Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. - Wikidata - wikimedia - TriplyDB

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.

http://www.wikidata.org/entity/Q42004966

about

Anaplastic lymphoma kinase: signalling in development and disease p130Cas mediates the transforming properties of the anaplastic lymphoma kinase Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.Essential role of PDK1 in regulating endothelial cell migration Autophagy regulates lipid metabolism Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.The heterogeneous landscape of ALK negative ALCL.RNAi-based screening identifies kinases interfering with dioxin-mediated up-regulation of CYP1A1 activity Nanopharmacology in translational hematology and oncology Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126 Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis.Autophagy in hypothalamic AgRP neurons regulates food intake and energy balance The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL.Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK.Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.Transfection of shRNA-encoding Minivector DNA of a few hundred base pairs to regulate gene expression in lymphoma cells Stathmin mediates hepatocyte resistance to death from oxidative stress by down regulating JNK.Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase gamma.Pathobiology of ALK+ anaplastic large-cell lymphoma.ALK-immunoreactive neoplasms.Mass spectrometry-based proteomic studies of human anaplastic large cell lymphoma.RNA-mediated gene silencing in hematopoietic cells.Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin.Distinct functions of JNK and c-Jun in oxidant-induced hepatocyte death.A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.Autophagy regulates adipose mass and differentiation in mice.Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer.Novel treatment avenues for peripheral T-cell lymphomas.Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.Molecular genetics of peripheral T-cell lymphomas.Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma.Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.

P2860

Q24312329-9BE63C60-2DDA-4D21-9266-D3BA3F9A21D4 Q24315788-46CFBCB6-18FE-4AB0-B5DC-DC4764725D3A Q24595585-019075A3-61EC-4EC1-B079-C06D8E9314F6 Q27851440-B8E18A31-1AA0-4BC1-8FCA-63CE1855AC39 Q28509286-4DE2D924-1FAA-4C7C-A619-2E2679E551BD Q29547421-70FAC9F0-F2AC-4040-9715-004FA5D98E3C Q30156817-DECCB6F0-9A38-464D-9BD1-98D877A66E81 Q30484934-E2DE954F-3224-45D1-8D9A-306FD7CCB99D Q33567012-90FD191A-A39C-4A2C-9220-6CF021E3A076 Q33867432-FE73BFC9-79CF-4A6B-8476-BEEAA56C4F4C Q33961538-2AB1436D-76C9-4917-BA01-229D08E54D70 Q34057987-CA72FC35-42B1-4C29-BCF8-30AFDAB29D44 Q34182453-BB32ACEE-680A-4B71-9762-F30A738AE92F Q34204941-216136A1-3CA6-4CC6-8CF2-5D7FC9468C07 Q34221605-A39FA626-0E47-4942-BDF1-83881C28CD1D Q34607749-EBBFC375-8D99-44EF-8493-FDE5DABA1D54 Q34657347-5B7CD9F9-9290-48FC-9A7A-2CA37C240194 Q35011473-3EFB9536-AFE4-41D1-9F19-CCD6D8AAD879 Q35086721-4742EC83-11A8-40D2-AA53-8B5098925746 Q35131224-43476A6A-49D7-47A4-B653-FEC701B1E9BB Q35159211-99B9C4BE-9B03-45FC-A94F-34E9172CE671 Q35303879-0807A958-B932-4120-A569-F5AF247DE5E7 Q35623435-3DE8ACF9-B4FA-4185-B653-B3E2003052E8 Q35950260-1930C866-8A29-4A79-A84D-D77F911DB510 Q36007756-132E82A9-1B6F-4057-BA6C-E8BF03422686 Q36092957-F366D986-4E75-4FBC-9122-115525ACDBCF Q36511656-FA714FA4-950D-45E4-9926-972AEB658D7B Q36631553-5F743F0B-86B0-412C-BE84-4963E42BB919 Q36771224-19CAD6A6-D281-43CF-8AA9-7084CD9BDF49 Q36795583-DC8258BB-A84A-42E1-9F68-76E7F5EA86F9 Q36893709-C4FBD5A6-F847-41C9-9D1F-00A2F72B32A9 Q37403082-1CCD5DAB-752A-4625-8DD6-35B2E2C90DF2 Q37863688-F639D63C-B25A-440A-972E-1BE4CDEFA36D Q37996424-8E4B2D0E-EF90-4ED3-BA39-5B7AEBF2E8EF Q38045460-AB2CD812-A81A-4404-B0C7-456D39E2A61C Q38183162-6E8DB4D4-F9D0-44D3-8985-7D3BD2ABED9D Q38183757-3E751581-E09E-44A4-9B57-294D0AC0DE85 Q38207137-0FA46610-6D57-4E28-9B15-63648ED4A054 Q38386866-8A9BCA58-E7CA-4D3F-9097-D88CB33DB508 Q38409231-EA33CA96-2904-4FA9-8191-B3FD75F78A4B

P2860

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.

http://www.wikidata.org/entity/Q42004966

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Ablation of oncogenic ALK is a ...... aplastic large-cell lymphomas.

@en

Ablation of oncogenic ALK is a ...... aplastic large-cell lymphomas.

@nl

type

label

Ablation of oncogenic ALK is a ...... aplastic large-cell lymphomas.

@en

Ablation of oncogenic ALK is a ...... aplastic large-cell lymphomas.

@nl

prefLabel

Ablation of oncogenic ALK is a ...... aplastic large-cell lymphomas.

@en

Ablation of oncogenic ALK is a ...... aplastic large-cell lymphomas.

@nl

P1433

Q42004966-04BAA768-AD42-4C7E-AECE-9FF485DB8200

P1476

Q42004966-383CABE4-7758-4950-B395-42E047DE1521

P2093

Q42004966-3CD3C6B5-2949-4103-A21A-D51F6D3095A5

Q42004966-54BAFB73-D355-4E1F-BF13-1017AC761076

Q42004966-8E4AE023-2B55-4DD4-9FAE-8E76619A15F1

Q42004966-8F8A1CA9-1440-4BD4-8C86-26B9E4E7AB4F

Q42004966-9D4D5FB0-55E2-42C1-9EFC-1D8C029F8B69

Q42004966-B0DA410F-B19F-4CE7-ADBF-7A61D5AC494A

Q42004966-B4448A7C-0C1B-4AF1-8E89-3FDE3465FD06

Q42004966-EDD56014-FA55-438C-851A-0CD53B1777E3

Q42004966-F2172F35-E79D-4D19-9850-FFB960DE4772

P2860

Q42004966-0114F3E3-563C-48F4-9EB3-0DC2C9C820C0

Q42004966-0209B626-5C7B-4754-8150-190532B34BA6

Q42004966-05315EDD-E0E2-4201-A188-ED74A3C508DA

Q42004966-0AD2B45E-4031-4B94-AA6F-D072BB736C66

Q42004966-0B397000-D332-4373-8E50-DCEB53248B81

Q42004966-0CD84025-178D-48D8-8D1C-1FF3EB122DAE

Q42004966-0DCD1A42-C44D-4846-AAA5-A24B57813BC8

Q42004966-0FC12B56-6083-4EAB-8201-82232EBC2881

Q42004966-18EE268F-84EE-4F76-84FD-0AB8F800F371

Q42004966-19572A10-0FFE-4D20-9F60-BEDA497BC4DA

P304

Q42004966-6BAB6020-9D3B-433E-9A24-F843F04333FB

P31

Q42004966-6D209A18-D0EB-4DEB-BE4D-261CF32BBAB8

P356

Q42004966-FD0EC1B3-2D8D-4B26-BC02-92C9C7C8DCB2

P407

Q42004966-FD296B91-475D-422F-A9A6-2202705C3C4E

P433

Q42004966-B46C5AC0-5390-4A3D-9062-894D43B87762

P478

Q42004966-D8AFADAE-911D-4C84-8509-9509BA9AFA29

P50

Q42004966-00B1E38C-D29E-4294-B95D-D35AE9AA367F

Q42004966-48663B6C-7766-4B9B-8FED-6AD142AD79C8

Q42004966-91171639-D718-4F0B-88DD-1FF90CEE916C

Q42004966-D459D9FD-E6D8-4DC7-ADDF-A9D636523E0E

Q42004966-DF9DFA07-FD0E-44E4-9C7E-F090572729E9

P577

Q42004966-17FC2CD4-A081-4233-92ED-99EEF386101D

P5875

Q42004966-015EC8E7-6C0F-4B82-B1A3-137EC4BF2786

P698

Q42004966-BC335F24-1A4E-420D-BCA3-347BB29CE5E5

P932

Q42004966-76D26582-D662-425E-B093-5C472D09ECF3

P356

BLOOD-2005-05-2125

P1433

P1476

Ablation of oncogenic ALK is a ...... aplastic large-cell lymphomas.

@en

P2093

Andrea D Manazza

http://www.w3.org/2001/XMLSchema#string

Carola Ponzetto

http://www.w3.org/2001/XMLSchema#string

Chiara Ambrogio

http://www.w3.org/2001/XMLSchema#string

Giorgio Inghirami

http://www.w3.org/2001/XMLSchema#string

Giorgio Palestro

http://www.w3.org/2001/XMLSchema#string

Riccardo Taulli

http://www.w3.org/2001/XMLSchema#string

Roberto Chiarle

http://www.w3.org/2001/XMLSchema#string

Valentina D'Escamard

http://www.w3.org/2001/XMLSchema#string

William Simmons

http://www.w3.org/2001/XMLSchema#string

P2860

p130Cas mediates the transforming properties of the anaplastic lymphoma kinase

Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity

Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.

A system for stable expression of short interfering RNAs in mammalian cells

Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death

Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

The emerging normal and disease-related roles of anaplastic lymphoma kinase

P304

689-697

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-05-2125

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Elisa Pellegrino

Roberto Chiarle

Giorgio Inghirami

Chiara Ambrogio

P577

2005-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7575759

http://www.w3.org/2001/XMLSchema#string

P698

16189272

http://www.w3.org/2001/XMLSchema#string

P932

1895619

http://www.w3.org/2001/XMLSchema#string